JBL Jabil Inc.

Jabil Healthcare Announces the Launch of the Qfinity™ Autoinjector Platform, a Reusable Drug Delivery Device with Broad Applicability

, a division of Jabil Inc. (NYSE: JBL), announces the launch of the ™ autoinjector platform, a simple, reusable and modular solution for subcutaneous (SC) drug self-administration, at a lower cost than market alternatives — supporting the emerging prioritization of sustainable drug delivery within the pharmaceutical industry.

Jabil Healthcare has been a trusted partner with the world’s leading healthcare brands for over 30 years, and now the company is excited to offer the Qfinity autoinjector platform, designed to help patients self-administer a variety of injectables, including larger volume, higher viscosity medicines. This represents the first time Jabil Healthcare will directly offer a drug delivery device platform.

“The Qfinity autoinjector platform is versatile with broad technical specifications for drug volumes and drug viscosities. It features a patient-centric form factor at up to 65% lower cost per injection than market-leading disposable autoinjectors,” said Oliver Eden, Business Unit Director, Jabil Healthcare. “Our product is intentionally designed to be sustainable and reusable at the core, all while being delivered at a lower cost than market alternatives.”

Medical waste is widely recognized as a challenge for the industry and the environment. A 2019 material study found that the highest percentage of medical-grade plastic waste is generated by plastic disposable syringes.1 To address this problem, the durable Qfinity autoinjector handles over 100 injections per device and accommodates 1 mL or 2.25 mL pre-filled disposable cassettes. Due largely to the fact that fewer components and material are consumed, it is estimated that the Qfinity autoinjector platform delivers up to a 65% reduction in cost per injection versus the market-leading disposable autoinjectors, as well as up to 60% reduction in carbon footprint per injection, 50% smaller manufacturing footprint and a 70% reduction in CAPEX. 2

The attractive handheld device is also available in a connected version, the Qfinity+ autoinjector, which enables medical teams to remotely monitor their patients’ care and compliance via built-in sensors and electronics — without any added complexity. The drive unit form factor and the user steps are exactly the same as the non-connected version. Capture and transmission of data operates seamlessly by virtue of the Qfinity+ Home Hub solution, which provides charging and seamless cellular data transfer functionality in near real-time without requiring input from the patient.3

“Qfinity+ enables connectivity without impacting ease of use, while enabling seamless data transfer at up to 20% lower cost per injection compared to unconnected, market-leading disposable autoinjectors. Within the disposable mechanical autoinjector market, a common route for delivering connectivity is a 'sleeve' that fits over the autoinjector and captures adherence and/or compliance and communicates those events to the user’s smartphone via Bluetooth. Jabil’s decision to instead develop the cellular Qfinity+ Home Hub solution goes back to our primary objective: maximizing access,” said Conor Mulcahy, Senior Director of Strategic Projects, Jabil.

The Qfinity autoinjector platform comes to market as one of the most versatile autoinjector solutions available today. It is sustainable, accessible and inclusive – both in ease of use and the seamless connectivity option it provides to address the new digital health environment.

“Pharma manufacturers have a significant opportunity to influence how the healthcare ecosystem evolves in solving today’s challenges with tomorrow’s solution. The way forward is to make life easier for patients, provide better tools for improving health and reduce medical waste,” said Eden.

1. “” ©2019 E-Health and Bioengineering, Ioana Marica, Mihaela Aluas, Simona Cinta Pinzaru, Babes-Bolyai University

2. Based on 100k patients per annum with weekly dosing vs. market-leading autoinjectors. Cost reduction will vary depending on dosage, frequency and patient pool.

3. Requires access to a cellular network, does not require wifi or smart phone.

About Jabil:

Jabil (NYSE: JBL) is a manufacturing solutions provider with over 260,000 employees across 100 locations in 30 countries. The world's leading brands rely on Jabil's unmatched breadth and depth of end-market experience, technical and design capabilities, manufacturing know-how, supply chain insights and global product management expertise. Driven by a common purpose, Jabil and its people are committed to making a positive impact on their local community and the environment. Visit to learn more.

EN
18/05/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Jabil Inc.

Jabil Inc: 1 director

A director at Jabil Inc sold 15,000 shares at 246.907USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Moody's Ratings assigns Baa3 rating to Jabil Inc.'s proposed senior un...

Moody's Ratings (Moody's) assigned Baa3 ratings to Jabil Inc.'s (Jabil) $900-$1,000 million proposed senior unsecured notes, which will be comprised of 2029 and 2033 maturities. The net proceeds from the proposed offerings will be used for general corporate purposes including repaying $500 million o...

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Jabil Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 4 June 2025 in which we reassessed the appropriateness of the ratings in the context of the rele...

 PRESS RELEASE

Jabil Posts Second Quarter Results

ST. PETERSBURG, Fla.--(BUSINESS WIRE)-- Today, Jabil Inc. (NYSE: JBL), reported preliminary, unaudited financial results for its second quarter of fiscal year 2025. Second Quarter of Fiscal Year 2025 Highlights: Net revenue: $6.7 billion U.S. GAAP operating income: $245 million U.S. GAAP diluted earnings per share: $1.06 Core operating income (Non-GAAP): $334 million Core diluted earnings per share (Non-GAAP): $1.94 “I am very pleased with our strong year-to-date results, which underscore the resilience and strength of our diversified portfolio. In Q2, we exceeded our expectations...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch